Roth’s $212 price target implies an additional upside of 32% for shares of Insmed, which have already rallied 160% in the last 12 months.
Communicating your story to the Street
Roth’s $212 price target implies an additional upside of 32% for shares of Insmed, which have already rallied 160% in the last 12 months.